Data at 2022 ASCO Annual Meeting Highlight Genentech’s Innovation
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody in heavily pre-treated patients with aggressive lymphoma, will be presented as part of...